Skip to main content

Table 1 The deregulated miRNAs that can be controlled by epigenetic drugs in human cancers

From: Regulation of microRNAs by epigenetics and their interplay involved in cancer

Epigenetically regulated miRNAs Target protein Cancer type Epigenetic drug Fold change Citation
Down-regulated      
miR-449 CDK6, CDC25A, c-MET Breast cancer DZNep + TSA >20 folds [50]
Hepatocellular carcinoma TSA 10-30 folds [31]
miR-125b PIGF Hepatocellular carcinoma 5-Aza-CdR >2 folds [51]
miR-126 VEGFA, PIK3R2 Bladder cancer 5-Aza-CdR + PBA >10 folds [52]
miR-127 BCL6 Bladder cancer and clear cell renal cell carcinomas 5-Aza-CdR + PBA/TSA >10 folds [5, 53]
miR-1-1 FOXP1, MET, HDAC4 Hepatocellular carcinoma 5-AzaC >20 folds [43]
miR-34 C-MYC, CDK6, Lung cancer, melanomas and prostate cancer 5-Aza-CdR >10 folds [54, 55]
miR-181a,b, miR-200a,b,c, and miR-203 BMI1 and RING2 Prostate cancer DZNep/5-Aza-CdR/SAHA 2-20 folds [32]
miR-31 SRC, RAB27a, NIK and MET, RhoA and WAVE3 Melanoma 5-Aza-CdR/DZNep >2 folds [24]
Breast cancer 5-Aza-CdR or 5-Aza-CdR + TSA >5 folds [25]
miR-29 Mcl-1, DNMT3A, DNMT3B,SP1, Tcl-1, CDK6 and IGR1F Aggressive B-Cell Lymphomas DZNep + SAHA 2-10 folds [10]
Chronic lymphocytic leukemia and acute myeloid leukemia LBH589/SAHA/AR-42 2-5 fold [15, 16]
miR-15a/miR-16 BCL-2 and MCL-1 Chronic lymphocytic leukemia LBH589/SAHA 2-5 fold [16]
miR-205 SIP1 and ZEP Prostate cancer 5-Aza-CdR >100 folds [37]
miR-21 PDCD4, TPM1, and MARCKS Prostate cancer 5-Aza-CdR >2 folds [37]
miR-370 IRS-1 Oral squamous cell carcinoma 5-Aza-CdR 2-20 folds [56]
miR-373 MBD2 Hilar cholangiocarcinoma 5-Aza-CdR or 5-Aza-CdR + TSA 2-5 folds [57]
miR-193b ETS1, CCND1, PLAU Prostate cancer 5-Aza-CdR + TSA >2 folds [58]
miR-132 HB-EGF,TALIN2 Prostate cancer 5-Aza-CdR or 5-Aza-CdR + TSA >5 folds [59]
miR-145 BNIP3, TNFSF10,PAK7 Prostate cancer and clear cell renal cell carcinomas 5-Aza-CdR or 5-Aza-CdR + TSA >2 folds [53, 60]
miR-141, miR-514 HGF, CDC42, RBX1, SLC2A1 Clear cell renal cell carcinomas 5-Aza-CdR + TSA >2 folds [53]
miR-335 SOX4, Rb1 Hepatocellular carcinoma 5-Aza-CdR + TSA >2 folds [61]
miR-205 BCL-w Prostate cancer 5-Aza-CdR 2-5 folds [62]
let-7 family RAS Nasopharyngeal carcinoma Zebularine 2-100 folds [63]
Up- regulated      
miR-224 API-5 Hepatocellular carcinoma C646 <50% [36]
miR-17-92 Cluster PTEN, BCL2L11, CDKN1A Colorectal Cancer SAHA or TSA 25%-67% [64]
  1. DNMT inhibitors: 5-azacytidine (5-AzaC); 5-aza-2′-deoxycytidine(5-Aza-CdR); Zebularine.
  2. HDAC inhibitors: suberoylanilide hydroxamic acid (SAHA); trichostatin A (TSA); panobinostat(LBH589); phenylbutyrate (PBA); OSU-HDAC42(AR-42).
  3. HAT inhibitors: C646.
  4. HMT inhibitors: 3-deazaneplanocin A (DZNep).